Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys

MT Newswires Live

Sep 13, 2024

Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys

Proteomics International Laboratories (ASX:PIQ) investors are left with "considerable unknowns" after the medical technology business terminated its exclusive license with Sonic Healthcare USA for its PromarkerD kidney disease diagnostic tool, according to a Wednesday note from Euroz Hartleys.

The license was canceled after certain milestones were not met, with the US launch now slated for 2025, targeting alternative pathology labs and service providers, and direct to consumers and patients.

While Proteomics has partners for Europe and other territories for PromarkerD, not commercializing in the US healthcare market, the world's largest, has lost potentially 32 million patients and potential users of the test, the investment firm said.

Euroz Hartleys downgraded Proteomics to hold from speculative buy and lowered the price target to AU$0.73 price target from AU$1.10 on increased uncertainties around the commercialization of PromarkerD in the US.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2467073007"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2467073007\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2467073007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 06:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467073007","market":"fut","top_or_hot":-1,"title":"Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys","media":"MT Newswires Live","content":"<html><body><p>Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys</p><p> Proteomics International Laboratories (ASX:PIQ) investors are left with \"considerable unknowns\" after the medical technology business terminated its exclusive license with Sonic Healthcare USA for its PromarkerD kidney disease diagnostic tool, according to a Wednesday note from Euroz Hartleys.</p><p>The license was canceled after certain milestones were not met, with the US launch now slated for 2025, targeting alternative pathology labs and service providers, and direct to consumers and patients.</p><p>While Proteomics has partners for Europe and other territories for PromarkerD, not commercializing in the US healthcare market, the world's largest, has lost potentially 32 million patients and potential users of the test, the investment firm said.</p><p>Euroz Hartleys downgraded Proteomics to hold from speculative buy and lowered the price target to AU$0.73 price target from AU$1.10 on increased uncertainties around the commercialization of PromarkerD in the US.</p></body></html>","source":"mtnewswires_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 06:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys Proteomics International Laboratories (ASX:PIQ) investors are left with \"considerable ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"Healthcare Svcs Group Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467073007","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467073007","pubTimestamp":1726179468,"columns":[],"sourceInfo":{"source_id":"mtnewswires_live","name":"MT Newswires Live"},"weMediaInfo":null,"summary":"Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Eu","collect":0,"end_time":0,"defaultTopTitle":"mtnewswires.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"Healthcare Svcs Group Inc","BK7508":"医药生物股","BK7048":"生命科学工具和服务","BK4211":"区域性银行","BK4137":"综合支持服务","ISBC":"投资者银行","SHL.AU":"SONIC HEALTHCARE LTD","BK7124":"保健护理服务","PIQ.AU":"PROTEOMICS INTERNATIONAL LAB"},"translate_title":"Euroz Hartleys表示，肾脏诊断许可证被取消后，蛋白质组学投资者面临“相当大的未知数”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"PIQ.AU":1,"SHL.AU":1,"ISBC":1},"content_text":"Proteomics Investors Face 'Considerable Unknowns' After Kidney Diagnostics License Canceled, Says Euroz Hartleys Proteomics International Laboratories (ASX:PIQ) investors are left with \"considerable unknowns\" after the medical technology business terminated its exclusive license with Sonic Healthcare USA for its PromarkerD kidney disease diagnostic tool, according to a Wednesday note from Euroz Hartleys.The license was canceled after certain milestones were not met, with the US launch now slated for 2025, targeting alternative pathology labs and service providers, and direct to consumers and patients.While Proteomics has partners for Europe and other territories for PromarkerD, not commercializing in the US healthcare market, the world's largest, has lost potentially 32 million patients and potential users of the test, the investment firm said.Euroz Hartleys downgraded Proteomics to hold from speculative buy and lowered the price target to AU$0.73 price target from AU$1.10 on increased uncertainties around the commercialization of PromarkerD in the US.","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}